[Company Logo Image] Compound validation and profiling in vitro and in vivo
Improved clinical predictability of preclinical studies
Subcutaneous and orthotopic human xenografts
Genetically modified organ specific tumour models
Receptor tyrosine kinase-driven breast cancer model

         Preclinical Concept Validation

Angiogenesis in vivo Model

       

Syngeneic tumour models
Pharmacokinetic studies
  Toxicology (GLP)
  Histology (Frozen Sections and Paraffin Embedded Sections)

                      

Home vivoPharm Search Employment Feedback

Up R&D News Services Management

 

Dr. Ralf Brandt (PhD), CEO & Director
Dr. Brandt is a biochemist and cell biologist, with over 15 years experience in research programs of experimental oncology. Furthermore, he has immense experience in in vivo pharmacology and anti-cancer drug profiling. He received his Licence (BSc in Biochemistry and Animal Physiology) in 1986, and his PhD (in Biochemistry) in 1991 from the Martin-Luther University of Halle-Wittenberg, Germany. In 1992 Dr. Brandt completed his post-doctoral training as Forgaty Fellow at the National Cancer Institute in Bethesda, MD and as a Research Fellow in the transgenic laboratory of the Schering AG, Germany. Since 1990 Dr. Brandt is active in the field of preclinical oncology, studying tumour growth and anti-cancer therapy in various in vitro and in vivo cancer models. He established several transgenic mouse lines developing tumours under the control of oncogenes (tyrosine receptor kinases). As head of the Tumour Biology program at Novartis Pharma AG, Switzerland, Dr. Brandt was developing sophisticated and predictive tumour models which are now available at vivoPharm. Under his leadership several tyrosine receptor kinase inhibitors and other anti-cancer drugs were profiled, developed and prepared for clinical trials. Furthermore, he was also leading studies to develop anti-angiogenic therapy using novel in vitro and in vivo models.
Dr. Brandt has developed a technology to produce organ based oncogene-driven syngeneic tumour models in mice and this know-how and technology is now available to vivoPharm.
 
 

Scientific Advisory Board

  will be announced soon
   
   

   

Send mail to webmaster@vivopharm.com with questions or comments about this web site.
Last modified: 18-Dec-2003